The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

cefprozil     (6R,7S)-7-[[(2R)-2-amino-2- (4...

Synonyms: SureCN37024, AG-H-79533, CTK8F8537, AC1L1Y5D, K690
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of cefprozil

 

High impact information on cefprozil

 

Chemical compound and disease context of cefprozil

 

Biological context of cefprozil

 

Anatomical context of cefprozil

  • The corresponding middle ear fluid concentrations of cefprozil ranged from 0.06 to 4.44 micrograms/ml and from 0.17 to 8.67 micrograms/ml, respectively [1].
  • A total of 108 college women with acute urinary tract infections were treated for 10 days with either 500 mg of cefprozil (BMY-28100-03-800) once a day (n = 72) or 250 mg of cefaclor three times a day (n = 36) [18].
  • The excretion of cefprozil into breast milk in nine healthy, lactating female subjects was investigated [19].
  • Plasma, tonsil, and adenoid samples were analyzed for cis and trans isomers of cefprozil by high-performance liquid chromatographic assays [3].
  • The in vivo effects of penicillin and cefprozil therapy on the interaction between organisms commonly recovered from inflamed tonsils were studied by using a subcutaneous abscess model in mice [20].
 

Associations of cefprozil with other chemical compounds

 

Gene context of cefprozil

  • Recombinant expression in Escherichia coli suggested that bla1 ( LVS ) did not encode a functional beta-lactamase, whereas bla2 ( LVS ) encoded a functional beta-lactamase that hydrolyzed penicillins but was inactive against third-generation cephalosporins, including cefprozil [16].
  • However, there were significantly more symptomatic patients among the bacteriological failures in the penicillin group (68.4%) than in the cefprozil group (26.7%). beta-Lactamase-producing Staphylococcus aureus was more frequently isolated from the throat flora during penicillin therapy than during cefprozil treatment [2].
  • In addition, during-therapy cultures for penicillin-treated patients yielded a significantly higher rate of beta-lactamase-producing Staphylococcus aureus than did those for the group of cefprozil-treated patients (13% vs. 4.5%, respectively; P = .046) [25].
  • Interfering AHS were more often recovered in patients treated with cefprozil [17].
  • Three hundred and thirty four children aged 6 months through 12 years with clinical symptoms and tympanic membrane signs of AOM received cefprozil 30 mg/kg/day in two divided doses per day for 10 days [26].
 

Analytical, diagnostic and therapeutic context of cefprozil

References

  1. Penetration of cefprozil into middle ear fluid of patients with otitis media. Shyu, W.C., Haddad, J., Reilly, J., Khan, W.N., Campbell, D.A., Tsai, Y., Barbhaiya, R.H. Antimicrob. Agents Chemother. (1994) [Pubmed]
  2. Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis. Milatovic, D., Adam, D., Hamilton, H., Materman, E. Antimicrob. Agents Chemother. (1993) [Pubmed]
  3. Penetration of cefprozil into tonsillar and adenoidal tissues. Shyu, W.C., Reilly, J., Campbell, D.A., Wilber, R.B., Barbhaiya, R.H. Antimicrob. Agents Chemother. (1993) [Pubmed]
  4. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. Clark, C., Bozdogan, B., Peric, M., Dewasse, B., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  5. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Nicolau, D.P., Onyeji, C.O., Zhong, M., Tessier, P.R., Banevicius, M.A., Nightingale, C.H. Antimicrob. Agents Chemother. (2000) [Pubmed]
  6. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Nagai, K., Davies, T.A., Jacobs, M.R., Appelbaum, P.C. Antimicrob. Agents Chemother. (2002) [Pubmed]
  7. Effects of time of administration and posture on the pharmacokinetics of cefprozil. Shyu, W.C., Gleason, C.R., Barbhaiya, R.H. Clinical pharmacokinetics. (1993) [Pubmed]
  8. Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Wiseman, L.R., Benfield, P. Drugs (1993) [Pubmed]
  9. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. Fogarty, C.M., Bettis, R.B., Griffin, T.J., Keyserling, C.H., Nemeth, M.A., Tack, K.J. J. Antimicrob. Chemother. (2000) [Pubmed]
  10. Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef. Biedenbach, D.J., Jones, R.N. J. Clin. Microbiol. (1994) [Pubmed]
  11. In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae. Nagai, K., Davies, T.A., Dewasse, B.E., Pankuch, G.A., Jacobs, M.R., Appelbaum, P.C. J. Antimicrob. Chemother. (2000) [Pubmed]
  12. Efficacy and tolerability of cefprozil versus amoxicillin/clavulanate for the treatment of adults with severe sinusitis. Adelglass, J., Bundy, J.M., Woods, R. Clinical therapeutics. (1998) [Pubmed]
  13. Treatment of upper and lower respiratory tract infections: clinical trials with cefprozil. Aronovitz, G. Pediatr. Infect. Dis. J. (1998) [Pubmed]
  14. Effect of antacid on the bioavailability of cefprozil. Shyu, W.C., Wilber, R.B., Pittman, K.A., Barbhaiya, R.H. Antimicrob. Agents Chemother. (1992) [Pubmed]
  15. Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor. Barbhaiya, R.H., Shukla, U.A., Gleason, C.R., Shyu, W.C., Pittman, K.A. Antimicrob. Agents Chemother. (1990) [Pubmed]
  16. The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics. Bina, X.R., Wang, C., Miller, M.A., Bina, J.E. Arch. Microbiol. (2006) [Pubmed]
  17. Effect of antimicrobial therapy with amoxicillin and cefprozil on bacterial interference and beta-lactamase production in the adenoids. Brook, I., Foote, P.A. The Annals of otology, rhinology, and laryngology. (2004) [Pubmed]
  18. Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women. Iravani, A. Antimicrob. Agents Chemother. (1991) [Pubmed]
  19. Excretion of cefprozil into human breast milk. Shyu, W.C., Shah, V.R., Campbell, D.A., Venitz, J., Jaganathan, V., Pittman, K.A., Wilber, R.B., Barbhaiya, R.H. Antimicrob. Agents Chemother. (1992) [Pubmed]
  20. Evaluation of bacterial interference and beta-lactamase production in management of experimental infection with group A beta-hemolytic streptococci. Brook, I., Gilmore, J.D. Antimicrob. Agents Chemother. (1993) [Pubmed]
  21. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Barbhaiya, R.H., Shukla, U.A., Gleason, C.R., Shyu, W.C., Wilber, R.B., Pittman, K.A. Antimicrob. Agents Chemother. (1990) [Pubmed]
  22. Absolute bioavailability of cefprozil after oral administration in beagles. Barbhaiya, R.H., Wang, L., Shyu, W.C., Pittman, K.A. Antimicrob. Agents Chemother. (1992) [Pubmed]
  23. The pharmacokinetics of the oral cephalosporins--a review. Wise, R. J. Antimicrob. Chemother. (1990) [Pubmed]
  24. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media. Block, S.L., Kratzer, J., Nemeth, M.A., Tack, K.J. Pediatr. Infect. Dis. J. (2000) [Pubmed]
  25. Treatment of pharyngitis and tonsillitis with cefprozil: review of three multicenter trials. McCarty, J.M., Renteria, A. Clin. Infect. Dis. (1992) [Pubmed]
  26. Efficacy and tolerability assessment of cefprozil in children with acute otitis media. Gupta, N., Bagga, V., Parmar, B.J., Kar, K., Mukherjee, A., Mehta, S., Moharana, A.K. Indian journal of pediatrics. (2004) [Pubmed]
 
WikiGenes - Universities